Connect with us

Business

Moderna’s stock gains 3.5% after it completes enrollment in COVID-19 vaccine trial – MarketWatch

Published

on

post featured image
ADVERTISEMENT

Shares of Moderna Inc.
MRNA,
+4.36%
gained 3.5% in trading on Thursday after it said it has completed enrollment of 30,000 participants in the Phase 3 clinical trial for its COVID-19 vaccine candidate. The trial is being conducted in partnership with the National Institutes of Health and the Biomedical Advanced Research and Development Authority. The preclinical company also said that 25,650 participants have received their second and final dose of the experimental vaccine in the late-stage trial,…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Electric vehicles are becoming more affordable and could cost less than gas-powered vehicles in just a few years – CBS News
Article feature image
The Biden administration moved more than $2 billion earmarked for COVID measures to deal with the influx of migrants at the border – Yahoo News
Article feature image
Cardano And Polygon Skyrocket To New All-Time Highs As Investors Seek Elon Musk’s Next Favorite Crypto – Benzinga